Replies to post #129488 on Biotech Values

[genisi]

The fact that BG-12 was not statsig better than Copaxone in the CONFIRM study does not mean that BG-12 isn’t better.

I think docs will see BG-12 as the more effective drug.

[masterlongevity]

"Here, I don’t agree. The fact that BG-12 was not statsig better than Copaxone in the CONFIRM study does not mean that BG-12 isn’t better. Lack of proof of superior efficacy is not the same as proof of lack of superior efficacy. Regards, Dew "

i agree, partly as well.

The burden of proof is on proving superiority and they did not prove superiority. All they can say now if they are both superior to PBO. From a sales and marketing standpoint, that's a big difference.

of course not proving supriority doesn't prove its the same.

But my assumption is that it is relative the same until superiority is proven, and that is also the assumption of the people who approve label at the FDA